## 5 Claims:

## 1. A thiomorpholino steroid compound of general formula I

10

## wherein in the moiety I' of compound I

15

20

each bond between between C<sup>5</sup> and C<sup>6</sup>, between C<sup>6</sup> and C<sup>7</sup>, between C<sup>7</sup> and C<sup>8</sup>, between C<sup>8</sup> and C<sup>9</sup>, between C<sup>8</sup> and C<sup>14</sup> and between C<sup>14</sup> and C<sup>15</sup>, independently, is a single bond or a double bond, at least one of these bonds being a double bond, with the proviso that there is no double bond in the steroid skeleton

## exclusively between C<sup>5</sup> and C<sup>6</sup>, and

wherein

5

10

15

R<sup>4</sup> and R<sup>4'</sup> independently, are selected from the group, comprising hydrogen and methyl.

- 2. The steroid compound according to claim 1, wherein in the moiety with general formula **I'** one double bond is present between C<sup>8</sup> and C<sup>14</sup> or two double bonds are present between C<sup>8</sup> and C<sup>9</sup> and between C<sup>14</sup> and C<sup>15</sup> or two double bonds are present between C<sup>5</sup> and C<sup>6</sup> and between C<sup>7</sup> and C<sup>8</sup>.
- 3. The steroid compound according to any one of claims 1 and 2, being selected from the group comprising:

(20S)-20-[(thiomorpholin-4-yl)methyl]-4,4-dimethyl-5 $\alpha$ -pregna-8,14-dien-3 $\beta$ -ol:

IA

20

(20S)-20-[(thiomorpholin-4-yl)methyl]-4,4-dimethyl-5 $\alpha$ -pregna-8(14)-en-3 $\beta$ -ol:

ΙB

5

(20S)-20-[(thiomorpholin-4-yl)methyl]- $5\alpha$ -pregna-8,14-dien-3 $\beta$ -ol:

IC

 $(20S)-20-[(thiomorpholin-4-yl)methyl]-4, 4-dimethyl-pregna-5, 7-dien-3\beta-ol$ 

10

(20S)-20-[(thiomorpholin-4-yl)methyl]-5α-pregna-8(14)-en-3β-ol:

5 IE.

> 4. A pharmaceutical composition comprising at least one thiomorpholino steroid compound of general formula I according to any one of claims 1 - 3 and at least one pharmaceutically acceptable excipient.

10

5. The pharmaceutical composition according to claim 4, wherein the steroid compound of general formula I is comprised in an effective amount.

15

6. A use of the thiomorpholino steroid compound of general formula I according to any one of claims 1 - 3 to the preparation of a pharmaceutical composition being useful to regulate reproduction, especially meiosis.

20

7. The use according to claim 6 for non-in vivo use.

8. A use of the thiomorpholino steroid compound of general formula I according to any one of claims 1 - 3 to the preparation of a contraceptive or of a profertility drug.

9. A method of regulating reproduction, especially meiosis, comprising administering to a subject in need of such a regulation an effective amount of at least one thiomorpholino steroid compound of general formula **I** according to any one of claims 1 - 3.

5

10. A method for improving the possibility of an oocyte's ability to develop into a mammal, comprising contacting an oocyte removed from the mammal with the thiomorpholino steroid compound according to any one of claims 1 - 3.

10

15

20

- 11. A method for the preparation of (20S)-20-[(thiomorpholin-4-yl)methyl]--4,4-dimethyl-5α-pregna-8,14-dien-3β-ol, comprising
  - a) starting from (20S)-20-hydroxymethyl-pregna-4-en-3-one;
  - b) introducing two alkyl groups in C<sup>4</sup> by alkylation;
  - c) reducing the keto group to a hydroxy group;
  - d) protecting the resulting hydroxy group with an acyl group;
  - e) introducing a  $\Delta^7$  double bond by bromination/dehydrobromination;
  - f) isomerizing the dien  $\Delta^{5,7}$  to the dien  $\Delta^{8,14}$  by heating in the presence of acid;
  - g) oxidizing the 17-hydroxy group to an aldehyde group;
  - h) reductively aminizing the aldehyde group with thiomorpholine and removing the acyl group by reduction reaction
- 25 12. The method according to claim 11, wherein the acyl group is a benzoate group.